Synthesis and antimicrobial activity of some imidazothiazole derivatives of benzofuran  by Shankerrao, Sheelavanth et al.
Arabian Journal of Chemistry (2017) 10, S554–S558King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESynthesis and antimicrobial activity of some
imidazothiazole derivatives of benzofuran* Corresponding author. Tel.: +91 9449140275.
E-mail address: ydbodke@gmail.com (Y.D. Bodke).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2012.10.018
1878-5352 ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Sheelavanth Shankerrao a, Yadav D. Bodke a,*, S. Santoshkumar ba Department of P.G. Studies and Research in Industrial Chemistry, School of Chemical Science, Jnana Sahyadri,
Kuvempu University, Shankaraghatta 577 451, Shivamogga, Karnataka, India
b Department of P.G. Studies and Research in Pharmaceutical Chemistry, Kuvempu University, P.G. Centre, Kadur 577 548,
Chikkamagaluru Dt., Karnataka, IndiaReceived 26 March 2012; accepted 31 October 2012
Available online 29 November 2012KEYWORDS
Anhydrous aluminum chlo-
ride;
1-(1-Benzofuran-2-yl)-2-
bromoethanone;
Imidazothiazoles;
Antibacterial;
AntifungalAbstract A series of 6-(1-benzofuran-2-yl)-3-phenyl imidazo[2,1-b][1,3]thiazole (5a–f) and 3,6-bis
(1-benzofuran-2-yl)imidazo[2,1-b][1,3]thiazole (6a–d) derivatives are synthesized by the reaction
of 1-(1-benzofuran-2-yl)-2-bromoethanones (2a–b) with 4-phenyl-1,3-thiazol-2-amines (4a–c) and
4-benzofurano-1,3-thiazol-2-amines (3a–b) respectively. The structures of newly synthesized com-
pounds are characterized by IR, 1H NMR and mass spectroscopic studies and were screened for
their antimicrobial activities. The preliminary results revealed that some of the compounds exhib-
ited promising antimicrobial activities.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Oxygen containing heterocycles are essential structural units
for medicinal chemists. Among the various heterocyclic com-
pounds, benzofuran derivatives occur predominately in nature
appreciable to their stability and ease of generation. Especially
benzofuran with its substituent(s) at C-2 and/or C-3 have at-
tracted a strong interest due to their widespread in a large
number of natural products and for their pronounced biolog-
ical activities such as antimicrobial (Abdel-Aziz and Mekawey,2009; Koca et al., 2005; Manna and Agrawal, 2009; Abdel-
Wahab et al., 2009), anti-inﬂammatory (Jadhav et al., 2008)
antioxidant (Chandrashekar et al., 2012; Gilbert et al., 2009),
anticancer (Galal et al., 2009; Chen et al., 2009), etc. On the
other hand, imidazothiazoles, a bicyclic (5,5)-fused system
with one bridgehead nitrogen atom possesses different biolog-
ical activities such as antipsychotic (Cole et al., 2007), anthel-
mintic, anti-inﬂammatory (Powers et al., 1981), anticoccidial
(Scribner et al., 2008), antitumor (Andreani et al., 2006;
Andreani et al., 2008; Andreani et al., 2005), etc. An imidazo-
thiazole derivative, Levamisole (the levo isomer of tetramisole)
is a broad spectrum anthelmintic, belonging to a general class
of agents called biologic response modiﬁers and has been orig-
inally designed for anthelmintic properties and also possesses
immuno-modulating and immuno-stimulating properties
(Kamal et al., 2005). Our research group reported the synthesis
of a series of novel bicyclic benzofuran heterocycles containing
bridgehead nitrogen atom, imidazo[2,1-b][1,3,4]thiadiazoles
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2010). The scattered reports on biological importance of both
benzofuran and imidazothiazole derivatives have speculated
us to design the molecules which encompass both benzofurans
and imidazothiazole together in one molecule (see Scheme 1).
In the present work, we have synthesized a series of 6-(1-
benzofuran-2-yl)-3-phenylimidazo[2,1-b][1,3]thiazole (5a–f)
and 3,6-bis(1-benzofuran-2-yl)imidazo[2,1-b][1,3]thiazole (6a–
d) derivatives and structures of these new compounds were
supported by the spectral data. All the synthesized compounds
were evaluated for antimicrobial activity by the agar well dif-
fusion method against one Gram-positive bacterial strain
(Staphylococcus aureus), three Gram-negative bacterial strains
(Pseudomonas Aeruginosa, Kleibsella Pneumonia, Escherichia
Coli) and two fungal strains (Aspergillus Niger, Candida albi-
cans). Ampicillin and Flucanozole were used as standard drugs
for antibacterial and antifungal activity respectively and di-
methyl formamide is used as solvent control.2. Experimental
All the chemicals used were of analytical grade. Melting points
were determined in open capillary and are uncorrected. Purity of
the compounds was checked by TLC on silica gel. The IR spectra
were recorded on aNicolet-Impact-410FT-IR spectrometer, using
KBR pellets. 1H NMR spectra were recorded on a Bruker super-
con FT NMR (400 MHz) spectrometer in CDCl3 or DMSO-d6
using TMS as an internal standard. The chemical shifts were ex-
pressed in d units. Mass spectra were recorded on a JEOL SX
102/DA-6000 (10 kV) FAB mass spectrometer.
2.1. General procedure for the synthesis of compounds 2(a–b)
Substituted 2-acetyl benzofuran (0.01 mol) 1(a–b) was dis-
solved in diethyl ether and catalytic amount of anhydrous
AlCl3 was added. The reaction ﬂask was kept in ice bath with
S556 S. Shankerrao et al.stirring and bromine (0.01 mol) was added to this solution
drop by drop for about 15–20 min. After complete addition,
stirring was continued for another 10 min. The solid mass sep-
arated was ﬁltered and washed with water and followed by pet
ether to get compounds 2(a–b).
2.1.1. 1-(1-Benzofuran-2-yl)-2-bromoethanone 2(a)
White crystalline solid (ethanol), yield 80%, mp 90–92 C, (lit.
mp 89 C). 1H NMR (DMSO-d6, 400 MHz): 8.098 (s, 1H),
8.074 (s, 1H), 7.883–7.911 (t, J= 11.2, 1H), 7.575–7.617 (m,
1H), 7.394–7.431 (t, 1H), 4.836 (s, 2H) MS: m/z= 238.1
(M+), 240.1 (M+ 2).
2.1.2. 2-Bromo-1-(5-bromo-1-benzofuran-2-yl) ethanone 2(b)
White solid (ethanol), yield 76%, mp 140–143 C, (lit. mp
140 C). 1H NMR (DMSO-d6, 400 MHz): 8.098 (s, 1H),
8.074 (s, 1H), 7.88–7.91 (t, 1H), 7.575–7.617 (m, 1H), 4.836
(s, 2H). MS: m/z= 316.2 (M+ 1), 318.2 (M+ 2), 320.2
(M+ 4).
2.2. General procedure for the synthesis of compounds 5(a–f) &
6(a–d)
A mixture of 1-(1-benzofuran-2-yl)-2-bromoethanone
(0.01 mol) 2a and 4-phenyl-1,3-thiazol-2-amines 4a, (0.01 mol)
was reﬂuxed in ethanol (25 ml) for 10 h. The progress of reaction
was monitored by TLC (mobile phase: ethyl acetatehexane,
2:8). After completion of the reaction, the reaction mixture
was cooled to room temperature and poured to cold water with
stirring. The resulting clear solution was neutralized with 5%
aqueous sodium bicarbonate solution; the separated solid mass
was ﬁltered and washed with water. The resulting compound
was recrystallized from ethanol to get pure compound 5a.
Compounds 5(b–f) were prepared by a similar method.
Compounds 6(a–d) were prepared by the reaction of 1-(1-ben-
zofuran-2-yl)-2-bromoethanones 2(a–b) and 4-(1-benzofuran-
2-yl)-1,3-thiazol-2-amines 3(a–b) using the above method.
2.2.1. 6-(1-Benzofuran-2-yl)-3-phenyl imidazo [2,1-
b][1,3]thiazole (5a)
Yellow solid (ethanol), yield 55%, mp 102–105 C, 1H NMR
(DMSO-d6, 400 MHz): 8.36 (s, 1H), 8.18 (s, 1H), 8.16 (s,
1H), 7.941 (d, J= 1.6 Hz, 1H), 7.89 (s, 1H), 7.85–7.87 (m,
2H), 7.58–7.62 (t, 1H), 7.49–7.52 (t, 1H), 7.45–7.48 (t, 2H),
7.32 (s, 1H). 13C NMR (CDCl3, 100.5 MHz): 102.6(1C),
107.6(1C), 111.5(1C), 115.9(1C), 120.9(1C), 122.1(1C),
123.3(1C), 123.8(1C), 124.6(1C), 127.8(2C), 128.4(1C),
129.3(2C), 133.2(1C), 136.0(1C), 150.1(1C), 155.3(2C). MS:
m/z= 317.3 (M+ 1).
2.2.2. 6-(5-Bromo-1-benzofuran-2-yl)-3-phenylimidazo [2,1-
b][1,3]thiazole (5b)
Yellow solid (ethanol), yield 62%, mp 120–124 C, 1H NMR
(DMSO-d6, 400 MHz): 8.36 (s, 1H), 8.18 (s, 1H), 7.94–7.95
(d, J= 3.6 Hz, 1H), 7.86 (s, 1H), 7.86–7.88 (m, 2H), 7.60–
7.63 (t, 1H). 7.48–7.49 (t, 1H), 7.47–7.51 (t, 2H), 7.29 (s,
1H). 13C NMR (CDCl3, 100.5 MHz): 102.6(1C), 107.6(1C),
111.5(1C), 114.0(1C), 116.8(1C), 121.0(1C), 122.5(1C),
123.7(1C), 124.6(1C), 127.8(2C), 128.4(1C), 129.3(2C),133.2(1C), 136.0(1C), 150.1(1C), 154.3(1C) 155.6(1C). MS:
m/z= 394.3 (M+), 396.3 (M+ 2).
2.2.3. 6-(1-Benzofuran-2-yl)-3-(4-methylphenyl) imidazo[2,1-
b][1,3]thiazole (5c)
Brown solid (ethanol), yield 65%, mp 95–98 C, 1H NMR
(DMSO-d6, 400 MHz): 8.34 (s, 1H), 8.19 (s, 1H), 8.12 (s,
1H), 7.94 (d, J= 1.6 Hz, 1H), 7.89 (s, 1H), 7.85–7.87 (m,
2H), 7.48–7.49 (t, 1H), 7.43–7.46 (t, 2H), 7.30 (s, 1H). 2.59
(s, 3H, CH3).
13C NMR (CDCl3, 100.5 MHz): 102.6(1C),
107.6(1C), 111.5(1C), 115.9(1C), 120.9(1C), 122.1(1C),
123.3(1C), 123.8(1C), 124.6(1C), 127.4(2C), 129.5(2C),
133.2(1C), 136.1(1C), 138.4(1C), 150.1(1C), 155.3(2C).
24.2(1C, CH3) MS: m/z= 331.0 (M+ 1).
2.2.4. 6-(5-Bromo-1-benzofuran-2-yl)-3-(4-methylphenyl)
imidazo [2,1-b][1,3]thiazole(5d)
Brown solid (ethanol), yield 59%, mp 110–113 C, 1H NMR
(DMSO-d6, 400 MHz): 8.36 (s, 1H), 8.18 (s, 1H), 7.94 (d,
J= 3.6 Hz, 1H), 7.86 (s, 1H), 7.86–7.88 (m, 2H), 7.48–7.497
(t, 1H), 7.47–7.51 (t, 2H), 7.34 (s, 1H), 2.6 (s, 3H, CH3).
13C
NMR (CDCl3, 100.5 MHz): 102.6(1C), 107.6(1C), 111.5(1C),
115.9(1C), 116.4(1C), 120.9(1C), 122.1(1C), 123.3(1C),
123.8(1C), 127.4(2C), 129.5(2C), 133.2(1C), 136.1(1C),
138.4(1C), 150.1(1C), 154.3(1C), 155.3(1C), 24.2(1C, CH3)
MS: m/z= 331.0 (M+ 1), 332.0 (M+ 2). MS: m/z= 409.3
(M+), 411.1 (M+ 2).
2.2.5. 6-(1-Benzofuran-2-yl)-3-(4-ﬂuorophenyl)imidazo[2,1-
b][1,3]thiazole (5e)
Yellow solid (ethanol), yield 56%, mp 97–100 C, 1H NMR
(DMSO-d6, 400 MHz): 8.34 (s, 1H), 8.19 (s, 1H), 8.12 (s,
1H), 7.94–7.94 (d, J= 1.6 Hz, 1H), 7.89 (s, 1H), 7.85–7.87
(m, 2H), 7.48–7.49 (t, 1H), 7.43–7.46 (t, 2H), 7.30 (s, 1H).
13C NMR (CDCl3, 100.5 MHz): 102.6(1C), 107.6(1C),
111.5(1C), 115.9(1C), 116.4(2C), 120.9(1C), 122.1(1C),
123.3(1C), 123.8(1C), 124.6(1C), 129.5(2C), 133.2(1C),
136.1(1C), 138.4(1C), 155.3(2C), 162.0 (1C). MS: m/
z= 335.3 (M+ 1), 336.3 (M+ 1).
2.2.6. 6-(5-Bromo-1-benzofuran-2-yl)-3-(4-
ﬂuorophenyl)imidazo[2,1-b][1,3]thiazole (5f)
Yellow solid (ethanol), yield 60%, mp 123–127 C, 1H NMR
(DMSO-d6, 400 MHz): 8.36 (s, 1H), 8.18 (s, 1H), 7.94
(d, J= 3.6 Hz, 1H), 7.86 (s, 1H), 7.86–7.88 (m, 2H), 7.48–
7.49 (t, 1H), 7.47–7.51 (t, J= 16, 2H), 7.34 (s, 1H). 13C
NMR (CDCl3, 100.5 MHz): 102.6(1C), 107.6(1C), 111.5(1C),
115.9(1C), 116.0(2C), 116.6(1C), 122.1(1C), 123.3(1C),
123.8(1C), 124.6(1C), 129.1(2C), 133.2(1C), 136.1(1C),
138.4(1C), 154.2(1C), 155.3(1C), 162.0(1C). MS: m/z= 412.2
(M+), 414.2 (M+ 2).
2.2.7. 3,6-Bis (1-benzofuran-2-yl)imidazo[2,1-b][1,3]thiazole
(6a)
Yellow solid (ethanol), yield 64%, mp 104–107 C, 1H NMR
(DMSO-d6, 400 MHz): 7.91 (s, 1H), 7.80–7.85 (m, 3H), 7.71–
7.73 (d, J= 8.4 Hz, 1H), 7.530–7.569 (t, 1H), 7.360–7.398 (t,
2H), 7.165–7.210 (t, 2H), 7.053 (s, 2H), 6.98 (s, 1H). 13C
NMR (CDCl3, 100.5 MHz): 102.7(2C), 107.6(1C), 111.3(2C),
119.2(1C), 119.9(2C), 123.3(1C), 123.8(2C), 124.2(2C),
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z= 357.0 (M+ 1).
2.2.8. 6-(1-Benzofuran-2-yl)-3-(5-bromo-1-benzofuran-2-yl)
imidazo[2,1-b][1,3]thiazole (6b)
Yellow solid (ethanol), yield 56%, mp 114–116 C, 1H NMR
(DMSO-d6, 400 MHz): 7.91 (s, 1H), 7.80–7.85 (m, 3H), 7.71–
7.73 (d, J= 8.4 Hz, 1H), 7.36–7.39 (t, 2H), 7.16–7.21 (t,
2H), 7.053 (s, 2H), 6.98 (s, 1H). 13C NMR (CDCl3,
100.5 MHz): 102.7(2C), 107.6(1C), 111.5(1C), 113.7(1C),
116.5(1C), 119.9(1C), 120.4(1C), 122.3(1C), 123.1(1C),
123.8(1C), 124.2(1C), 124.7(1C), 126.2(1C), 129.1(1C),
136.0(1C), 147.8(1C), 149.4(2C), 154.1(1C), 155.6(1C). MS:
m/z= 434.2 (M+), 436.2 (M+ 2).
2.2.9. 3-(1-Benzofuran-2-yl)-6-(5-bromo-1-benzofuran-2-
yl)imidazo[2,1-b][1,3]thiazole (6c)
Yellow solid (ethanol), yield 67%, mp 94–97 C, 1H NMR
(DMSO-d6, 400 MHz): 7.88 (s, 1H), 7.81–7.85 (m, 3H), 7.73
(d, J= 10 Hz, 1H), 7.36–7.39 (t, 2H), 7.16–7.21 (t, 2H),
7.053 (s, 2H), 6.98 (s, 1H). 13C NMR (CDCl3, 100.5 MHz):
102.7(2C), 107.6(1C), 111.5(1C), 113.7(1C), 116.5(1C),
119.9(1C), 120.4(1C), 122.3(1C), 123.1(1C), 123.8(1C),
124.2(1C), 124.7(1C), 126.2(1C), 129.1(1C), 136.0(1C),
147.8(1C), 149.4(2C), 154.1(1C), 155.6(1C). MS: m/z= 434.2
(M+), 436.2 (M+ 2).
2.2.10. 3,6-Bis (5-bromo-1-benzofuran-2-yl)imidazo[2,1-
b][1,3]thiazole (6d)
Yellow solid (ethanol), yield 61%, mp 103–106 C, 1H NMR
(DMSO-d6, 400 MHz): 7.98 (s, 1H), 7.81–7.85 (m, 2H), 7.75
(d, J= 10.8 Hz, 1H), 7.36–7.39 (t, 2H), 7.16–7.21 (t, 2H),
7.053 (s, 2H), 6.98 (s, 1H). 13C NMR (CDCl3, 100.5 MHz):
102.7(2C), 107.5(1C), 113.3(2C), 116.4(2C), 120.1(1C),
122.8(1C), 124.1(2C), 126.2(2C), 129.4(2C), 136.3(1C),
146.0(1C), 147.8(2C), 155.6(2C). MS: m/z= 514.1 (M+),
516.1 (M+ 2). 518.1 (M+ 4).
2.3. Antimicrobial activity
All the newly synthesized compoundswere dissolved in dimethyl
formamide (DMF) to prepare stock solution at the concentra-
tion of 1 mg/mL. The antimicrobial activity was carried out by
the agar-well diffusion method which is a simple susceptibility
screening method (Bayrak et al., 2009). Each microorganism
was suspended in nutrient broth and diluted approximately col-
ony forming unit (cfu) per mL. They were ‘ﬂood-inoculated’
onto the surface of nutrient agar and then dried. Five-millimeter
diameter wells were cut from the agar using a sterile cork-borer;
50 lL and 100 lL of the test compound solution were delivered
into the wells. The plates were incubated for 32 h at 35 C. Anti-
microbial activity was evaluated by measuring the zone of inhi-
bition against the test organisms.3. Result and discussion
3.1. Chemistry
Earlier the key intermediates 1-(1-benzofuran-2-yl)-2-bromo-
ethanone 2(a–b) were synthesized in our laboratory by thebromination of 2-acetyl benzofuran using bromine in acetic
acid which was a more tedious method (Venkatesh and Bodke,
2010). In the present work we have synthesized the key inter-
mediate more efﬁciently using catalytic amount of AlCl3 in
non aqueous solvent diethyl ether by direct addition of bro-
mine to accomplish product within 30 min with about 96%
of purity. The structure was conﬁrmed by spectral analysis
and by comparing the melting points with the literature value.
The reaction of 1-(1-benzofuran-2-yl)-2-bromoethanones
2(a–b) with thiourea in ethanol furnished 4-(1-benzofuran-2-
yl)-1,3-thiazol-2-amines 3(a–b). Substituted 4-phenyl-1,3-thia-
zol-2-amines 4(a–c) were prepared by the literature method
(Siddiqui et al., 2006).
2-Aminothiazoles are known to react with 2-halo ketones
to form imidazo[2,1-b]thiazoles through cyclization involving
the 2-imino, carbonyl functions (El-Taweel and Elnagdi,
2000; Burger and Ullyot, 1947; Toan and Tefas, 1962). The ti-
tle compounds 5(a–f) and 6(a–d) were synthesized by reacting
1-(1-benzofuran-2-yl)-2-bromoethanones 2(a–b) as a haloke-
tone with 4-phenyl-1,3-thiazol-2-amines 4(a–c) and 4-(1-ben-
zofuran-2-yl)-1,3-thiazol-2-amines 3(a–b) derivatives
respectively. The structures of these compounds were con-
ﬁrmed by spectral data. The chemical structures of all synthe-
sized compounds were further conﬁrmed by 1H and 13C NMR
spectral data. In the 1H NMR spectra of compounds 5c and
5d, we found a singlet at o2.6 ppm corresponding to three
methyl protons and the multiplet in the range of o6.70–
8.37 ppm due to aromatic protons. The resonance of different
carbons at o115.79–157.48 ppm was attributed to aromatic
carbons. On varying the substitution on the same carbon the
shift in the resonance frequency was observed. For example
when C–H in compound 6a (o123.3 ppm) was replaced with
C–Br, 6b (o116.5 ppm), upﬁeld shift of o6.8 ppm was observed.
Further the structures of the new compounds were supported
by mass spectral analysis.
3.2. Anti microbial activity
All the synthesized compounds were screened for their antibac-
terial and antifungal activities at two different concentrations
and the results are shown in Table 1. The results revealed that
most of the synthesized compounds showed variable degrees of
inhibition against the tested microorganisms.
3.2.1. Antibacterial activity
Compounds 5b and 6b showed an excellent effect at both the
tested concentrations against S. aureus, P. aeruginosa and
Enterococcus feltis, whereas the same compounds revealed mod-
erate activity against Klbesilla pneumona and E. coli (Table 1).
Compounds 5e and 5f showed excellent activity againstS. aureus
and E. coli.On the other hand, compounds 5a, 5c, 6c and 6d dis-
played moderate activity against all bacterial species.
3.2.2. Antifungal activity
Antifungal activity was carried against two human pathogen
fungal species A. Niger and Trichoderma Virdae. The results
obtained from the present study recorded a remarkable differ-
ence in the antifungal effect of all tested compounds at both
the concentrations (Table 1). Compounds 5b, 5c and 6d
showed excellent activities against both the tested organisms
whereas compounds 5d and 6a showed moderate activity and
Table 1 Antimicrobial activity data (Zone of inhibition in mm).
Comp. no. S. aureus K. pneumona P. aeruginosa E. Coli A. Niger T. viradae
50 lL 100 lL 50 lL 100 lL 50 lL 100 lL 50 lL 100 lL 50 lL 100 lL 50 lL 100 lL
5a 12 16 09 16 08 12 12 16 10 12 07 09
5b 20 27 16 22 18 25 15 18 19 22 15 19
5c 20 24 06 09 12 19 10 12 22 26 24 26
5d 18 22 12 18 – 08 15 22 14 20 23 25
5e 14 17 06 16 12 14 18 20 06 12 14 20
5f 18 22 – 10 14 18 16 20 08 12 14 20
6a 08 10 13 18 – – – – 14 16 13 18
6b 23 28 13 18 18 24 12 16 08 10 08 12
6c 15 23 06 14 12 18 16 20 06 08 12 16
6d 18 22 12 18 – 12 15 22 23 26 21 25
Ampicillin 24 30 28 32 20 28 28 31 – – – –
Flucanozole – – – – v – – – 28 34 28 30
S558 S. Shankerrao et al.compounds 5a, 5e, 5f, 6b and 6d showed weak antifungal activ-
ity against both the tested organisms.Acknowledgements
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